ArticlePDF Available

Relapse-Prevention Booklets as an Adjunct to a Tobacco Quitline: A Randomized Controlled Effectiveness Trial

Authors:

Abstract and Figures

Relapse prevention (RP) remains a major challenge to smoking cessation. Previous research found that a set of self-help RP booklets significantly reduced smoking relapse. This study tested the effectiveness of RP booklets when added to the existing services of a telephone quitline. Quitline callers (N = 3458) were enrolled after their 2-week quitline follow-up call and randomized to one of 3 interventions: (1) Usual Care (UC): standard intervention provided by the quitline, including brief counseling and nicotine replacement therapy; (2) Repeated Mailings (RM): 8 Forever Free RP booklets sent to participants over 12 months; and (3) Massed Mailings (MM): all 8 Forever Free RP booklets sent upon enrollment. Follow-ups were conducted at 6-month intervals, through 24 months. The primary outcome measure was 7-day-point-prevalence-abstinence. Overall abstinence rates were 61.0% at baseline, and 41.9%, 42.7%, 44.0%, and 45.9% at the 6-, 12-, 18- and 24-month follow-ups, respectively. Although RM produced higher abstinence rates, the differences did not reach significance for the full sample. Post-hoc analyses of at-risk subgroups revealed that among participants with high nicotine dependence (n=1593), the addition of RM materials increased the abstinence rate at 12 months (42.2% versus 35.2%; OR=1.38; CI=1.03 -1.85; p=.031) and 24 months (45% versus 38.8%; OR=1.31; CI=1.01-1.73; p=.046). Sending self-help RP materials to all quitline callers appears to provide little benefit to deterring relapse. However, selectively sending RP booklets to callers explicitly seeking assistance for relapse prevention and those identified as highly dependent on nicotine might still prove to be worthwhile. © The Author 2015. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Content may be subject to copyright.
Nicotine & Tobacco Research, 2015, 1–8
doi:10.1093/ntr/ntv079
Original investigation
© The Author 2015. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
1
Introduction
Long-term smoking cessation is related to decreased mortality and mor-
bidity,1–3 yet most smokers who achieve short-term abstinence eventu-
ally relapse to smoking. Among self-quitting smokers, the relapse rate
may be as high as 95%.4 Among smokers receiving cessation treatment,
70% relapse.5 Even among smokers who successfully abstain for one
full year, 10% eventually return to regular smoking.6 Consequently,
effective interventions aimed at relapse prevention (RP) are essential
for long-term cessation and decrease in smoking-related illness.
Cognitive behavioral counseling combined with pharmaco-
therapy is the most effective evidence-based approach to smoking
Original investigation
Relapse-Prevention Booklets as an Adjunct to
a Tobacco Quitline: ARandomized Controlled
EffectivenessTrial
MarinaUnrod PhD1,2, Vani N.Simmons PhD1,2, Steven K.Sutton PhD1, K.
MichaelCummings PhD3, PaulaCelestino BS4, Benjamin M.Craig PhD1,2,
Ji-HyunLee PhD5, Lauren R.Meltzer BA1,2, Thomas H.Brandon PhD1,2
1Department of Health Outcomes and Behavior, H.Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
2Department of Psychology, University of South Florida, Tampa, FL; 3Department of Psychiatry and Behavioral
Sciences, Medical University of South Carolina, Charleston, SC; 4Department of Health Behavior Roswell Park Cancer
Institute, Buffalo, NY; 5Department of Internal Medicine University of New Mexico Cancer Center, Albuquerque, NM
Corresponding Author: Thomas H.Brandon, PhD, Tobacco Research and Intervention Program, Department of Health
Outcomes and Behavior, Moffitt Cancer Center, 4115 E.Fowler Avenue, Tampa, FL 33617, USA. Telephone: 813-745-1750;
Fax: 813-449-8247; E-mail: thomas.brandon@moffitt.org
Abstract
Introduction: Relapse prevention (RP) remains a major challenge to smoking cessation. Previous
research found that a set of self-help RP booklets significantly reduced smoking relapse. This study
tested the effectiveness of RP booklets when added to the existing services of a telephone quitline.
Methods: Quitline callers (N=3458) were enrolled after their 2-week quitline follow-up call and
randomized to one of three interventions: (1) Usual Care: standard intervention provided by the
quitline, including brief counseling and nicotine replacement therapy; (2) Repeated Mailings (RM):
eight Forever Free RP booklets sent to participants over 12months; and (3) Massed Mailings: all
eight Forever Free RP booklets sent upon enrollment. Follow-ups were conducted at 6-month inter-
vals, through 24months. The primary outcome measure was 7-day-point-prevalence-abstinence.
Results: Overall abstinence rates were 61.0% at baseline, and 41.9%, 42.7%, 44.0%, and 45.9% at the
6-, 12-, 18- and 24-month follow-ups, respectively. Although RM produced higher abstinence rates,
the differences did not reach significance for the full sample. Post-hoc analyses of at-risk subgroups
revealed that among participants with high nicotine dependence (n=1593), the addition of RM
materials increased the abstinence rate at 12months (42.2% vs. 35.2%; OR=1.38; 95% CI=1.03% to
1.85%; P=.031) and 24months (45% vs. 38.8%; OR=1.31; 95% CI=1.01% to 1.73%; P=.046).
Conclusions: Sending self-help RP materials to all quitline callers appears to provide little benefit to
deterring relapse. However, selectively sending RP booklets to callers explicitly seeking assistance
for RP and those identified as highly dependent on nicotine might still prove to be worthwhile.
Nicotine & Tobacco Research Advance Access published April 24, 2015
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 002
cessation.5 Counseling interventions usually include and emphasize
RP. However, very few smokers use counseling, often citing incon-
venience.7 Therefore, the public health impact of this approach has
been limited by poor population reach. On the other hand, telephone
quitlines are effective5,8 and offer convenience as well as high cost-
effectiveness relative to most other interventions for smoking cessa-
tion.9–13 Quitlines currently exist in all US states and throughout the
world, reaching a large proportion of smokers annually.14 However,
as with other cessation interventions, the rate of smoking relapse
among quitline users remains high.15–19
A recent meta-analysis found that self-help approaches (ie, mini-
mal interventions such as written materials) were the only empiri-
cally-supported interventions for preventing smoking relapse.20 One
such self-help intervention was found to be efcacious and cost-effec-
tive among recently quit smokers.21–23 This intervention comprises a
series of booklets, called Forever Free, with content that draws on
empirical and theoretical research in RP.24–25 Aquasi-experimental
study previously found that these booklets also reduced relapse
among callers to a state tobacco quitline, but only among those
who had not received pharmacotherapy.26 Additionally, a modied
version of the booklets was found to reduce postpartum smoking
relapse among lower income women.27
The Forever Free intervention offers potential for further enhanc-
ing public health impact by adding a low-cost relapse-prevention
component to existing telephone quitlines. The goal of the current
study was to test the real-world effectiveness of adding the relapse-
prevention booklets to the services of an existing state quitline. Based
upon our previous research,21–22 we hypothesized that the Forever
Free booklets would improve the long-term abstinence rates among
adult smokers calling a telephone quitline. Although the booklets
were originally developed to be distributed over 12months,21 they
were subsequently found to be equally efcacious and more cost-
effective among self-quitters when delivered all at once.22 Hence, the
two different distribution schedules were tested in the current clini-
cal trial, with no specic hypothesis regarding their relative effective-
ness for quitline callers.
Methods
Design Overview
A randomized three-arm equal allocation design was used to test the
effectiveness of the Forever Free booklets among state quitline call-
ers. The three conditions included: (1) Usual care (UC), comprised of
the standard interventions provided by the New York State Smokers’
Quitline (NYSSQL); (2) Repeated Mailings (RM), which included
UC, plus the eight Forever Free booklets sent to participants over a
12-month period; and (3) Massed Mailings (MM), which included
UC, plus the eight Forever Free booklets sent to participants all at
once. Assessments occurred at 6-month intervals, through 24months.
Participants
Participants were clients of the NYSSQL. The inclusion criteria were
(1) smoked at least 10 cigarettes per day over the month prior to call-
ing the quitline; (2) at least 18years old; (3) able to speak and read
English; and (4) reached by the NYSSQL at their 2-week call back
(see Procedures). Because quitline callers were offered smoking ces-
sation medication, exclusion criteria included pregnancy or breast-
feeding, heart attack or stroke within the past 2 weeks, current use
of bupropion or varenicline, and serious cardiovascular problems
(unless approved by their physician). There was no racial or gender
bias in the selection of participants. Although the intervention was
initially developed for individuals who had already achieved short-
term abstinence, the intent of this effectiveness trial was to facili-
tate dissemination by minimizing burden to the quitline operators.
Therefore, tobacco abstinence was not an inclusion criterion.
Procedures
This study was approved by the Institutional Review Boards at
the University of South Florida and Roswell Park Cancer Institute.
When smokers called the NYSSQL, an initial interview included col-
lection of basic demographic information, smoking history, and eli-
gibility screening for nicotine replacement therapy (NRT). Eligible
smokers were then mailed 2 weeks of NRT. Approximately 2 weeks
(10–14 days) following initial contact, quitline specialists called
clients back to verify that they had received the NRT, provide any
additional assistance, and inform eligible clients about the oppor-
tunity to participate in the relapse-prevention clinical trial. Clients
were invited to “participate in a study to develop better ways to pro-
vide educational materials about quitting smoking.Approximately
50%–70% of eligible NYSSQL clients were randomly selected and
invited into the study per month until the required sample size was
reached. Participants were recruited between October 2009 and
April2010.
Upon providing verbal approval, participants were randomized
(without stratication or blocking) to 1 of 3 treatment conditions
and contact information was acquired. Random allocation sequence
was generated by NYSSQL research team using a pseudo-random
number generator algorithm using a seed value of number of sec-
onds from midnight at the time of the call. The quitline specialists
inviting clients to participate in the study were not aware of the
treatment assignment. All assessments (baseline and follow-up) and
intervention materials were sent to participants via US mail. The
treatment implementation and research roles were separated by site:
the NYSSQL team sent all intervention materials at appropriate time
points, and the Moftt Cancer Center research team sent and received
all of the assessment questionnaires. Receipt of the completed base-
line questionnaire constituted consent for participation and enroll-
ment into the study. Follow-up assessments were conducted via mail
at 6-month intervals through 24months. Participants were paid $20
for completing each assessment questionnaire, with a bonus pay-
ment of $50 if they completed all ve assessments.
Intervention Conditions
Usual Care Condition
This condition comprised the standard intervention provided to cur-
rent smokers who called the NYSSQL. It included the initial contact
call and coaching interview, provision of a 2-week starter kit of NRT
(client had a choice of nicotine transdermal patch, nicotine gum, or
nicotine lozenge), and a 2-week proactive follow-up coaching tel-
ephone call. A“Ready to Quit” kit was mailed to current smokers
after the initial call and included a congratulatory cover letter, a “Break
Loose” stop smoking guide, a medications chart, and two single-page
fact sheets about dealing with nicotine withdrawal and maintaining
abstinence.
Repeated Mailing Condition
This condition comprised UC, plus eight Forever Free relapse-
prevention booklets delivered as originally developed.21 The rst
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 00 3
booklet was mailed after participants were enrolled into the study,
and the rest were mailed at the following time points: 1, 2, 3, 5, 7, 9,
and 12months. The rst booklet, “An Overview,” provides a general
overview about quitting smoking, and each of the remaining seven
booklets include more extensive information on topics related to
maintaining abstinence: Smoking Urges; Smoking and Weight; What
if You Have a Cigarette?; Your Health; Smoking, Stress, and Mood;
Lifestyle Balance; and Life without Cigarettes. The content of the
booklets is based on cognitive-behavioral theory24,28 and draws upon
principles that typically represent the key relapse-prevention coun-
seling interactions that occur in the clinical setting. They are written
at the fth to sixth grade reading level to maximize their accessibility
to a wide range of individuals.29 The printing cost of the eight book-
lets was $5.58 per person.
Massed Mailing Condition
This condition comprised UC, plus the identical eight booklets as in
the RM condition, but all of the booklets were sent to participants in
a bundle upon study enrollment.
Measures
Baseline Measures
Demographic and smoking-related characteristics were assessed. The
Fagerström Test for Nicotine Dependence,30 a standard, validated
6-item questionnaire, assessed tobacco dependence. Motivation to
stop smoking was assessed via the Contemplation Ladder31 and the
Stages of Change algorithm.32 The Abstinence-Related Motivational
Engagement scale,33 a 16-item questionnaire, was used to measure
post-cessation commitment to remaining smoke-free as evidenced
by level of involvement in the quitting and maintenance process.
Participant evaluation of the quitline services was assessed using the
Client Satisfaction Questionnaire (CSQ).34 The items were rated on a
scale of 1–4, with a total score range of 7–28. Ave-point item was
used to measure condence in being smoke-free in 6months. Finally,
current and past use of smoking cessation interventions and cessa-
tion aids were assessed.
Follow-up Measures
At each follow-up, tobacco, and any use of pharmacotherapy or
other smoking cessation assistance since the previous contact were
assessed. Motivation to quit smoking, including the Contemplation
Ladder, the Stages of Change algorithm, the Abstinence-Related
Motivational Engagement, the CSQ, and the one-item measure of
condence to be smoke-free in 6months were assessed. Eight CSQ-
based items assessed participants’ evaluation of the Forever Free
booklets. The CSQ items were rated on a scale of 1–4, with a total
score range of 8–32. Participants in the two Forever Free treatment
conditions reported at 12, 18, and 24months which of the eight
booklets they received. The primary outcome measure was 7-day
point-prevalence abstinence.
SampleSize
Sample size was selected to detect minimum differences of 5% in the
primary outcome measure (abstinence rates between pairs of condi-
tions) using generalized estimating equation analyses. Apriori sample
size calculation indicated that at least 1133 smokers per condition
would provide 80% power to detect differences under conservative
assumptions about both the possible range of abstinence rates of UC
condition and rates of attrition over the course of the study.
Statistical Analyses
Data analyses occurred in 2013–2014. Baseline demographic and
smoking characteristics were compared across treatment conditions
using one-way analyses of variance and chi-square tests, depending
on the characteristics of the variable being tested. Satisfaction with
quitline services at baseline and satisfaction with treatment at 6- and
12-month follow-ups was compared across the treatment condi-
tions using analyses of variance. The primary hypotheses (Forever
Free conditions vs. UC) were assessed using generalized estimating
equations with an autoregressive working correlation structure. In
the base model, treatment, time, and their interaction were used to
predict 7-day point-prevalence across the four follow-ups. Potential
moderators were tested individually by adding the moderator and
associated interaction terms to the basemodel.
We used multiple imputation to handle missing data, which
occurred primarily because of follow-up surveys not being returned
at each of the four follow-up time-points (Figure1). Our imputa-
tion approach used a Markov Chain Monte Carlo method35 which is
based upon a missing at random assumption. Twenty imputed data
sets were generated via PROC MI procedure in SAS software (SAS,
version 9.3). The procedure incorporated 16 variables and 12 inter-
action terms: (1) smoking status at baseline and the four follow-ups,
(2) the predictors for the models being tested (ie, treatment condition
plus seven demographic and four smoking-related variables to be
assessed as moderators), and (3) 12 computed variables representing
the interaction of a moderator variable with treatment. Binary smok-
ing status at each follow-up was nalized using adaptive rounding.36
Results
Recruitment and Baseline Demographics
The CONSORT ow diagram is presented in Figure1. Of the 7589
NYSQL clients invited to participate in the study, 5752 (76%) pro-
vided preliminary verbal consent and were randomized to treatment
conditions. Of those randomized, 3458 (60%) returned the base-
line questionnaire indicating consent and were enrolled in the study.
Follow-up return rates did not differ statistically between groups.
Participant characteristics at baseline are presented in Table 1.
Comparisons of the UC group with each of the two Forever Free
groups revealed two signicant differences. There was a higher per-
centage of males in the RM group (56.6%) compared to UC group
(51.7%), X2(1)=5.50, P=.019. In addition, participants in the MM
group reported a higher average cigarettes per day (20.3) compared to
those in the UC group (19.2), t(2306)=2.95, P=.009. Controlling for
these differences did not affect the primary cessation outcome results.
Survey ReturnRates
Follow-up survey return rates decreased over time (Figure1): 51.9%
returned all four follow-ups, with no group differences, and 15.6%
returned none of the follow-ups, with a lower percentage of those
in the UC group (13.0%) than in the MM (16.0%) and the RM
(17.8%) groups (Ps < .05). Compared to those who returned at least
one follow-up survey, participants who did not return any follow-up
surveys were more likely to be abstinent at baseline, female, a racial
and/or ethnic minority, married, uninsured, and younger (Ps < .01).
Treatment Satisfaction
On average, participants were highly satised with the services they
received from the NYSSQL. The overall mean score on the CSQ at
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 004
baseline was 25.47 (SD=2.85). There were no differences between
the three treatment groups on satisfaction with NYSSQL services.
Similarly, participants in the two Forever Free treatment conditions
reported high levels of satisfaction with the intervention booklets.
The overall mean score on the CSQ at the 6-month follow-up was
25.76 (SD=4.61). At 12months, the time by which the RM group
participants have received all of the intervention booklets, the over-
all mean score on the CSQ was 26.09 (SD= 4.69). There were no
differences between the MM and RM groups on satisfaction with
the Forever Free intervention materials at either time-point.
Cessation Outcomes
Table2 presents abstinence rates for each condition at each time
point. The 7-day point-prevalence abstinence rate for the entire sam-
ple at baseline was 61%. The overall abstinence rates were 41.9%,
42.7%, 44%, and 45.9% at the 6-, 12-, 18-, and 24-month follow-
ups, respectively. The RM intervention consistently produced some-
what higher abstinence rates than the UC and MM interventions.
However, generalized estimating equation analyses comparing either
MM or RM against UC did not nd signicant group differences
or group × time interactions. Analyses of smoking status at follow-
up among the subset of participants (n= 2108) who had achieved
abstinence by the baseline assessment (the true target of RP) also
failed to reveal signicant group differences in outcomes, with simi-
lar patterns of abstinence rates across conditions, but higher rates of
abstinence overall. For example, at 24months, the abstinence rates
were 57.2%, 55.5%, and 61.7% for the UC, MM, and RM condi-
tions, respectively.
None of the demographic or smoking-related variables presented
in Table 1 were found to be signicant moderators of the treat-
ment effect. Post-hoc analyses were performed to compare the RM
and UC participants based on “at-risk” subgroups, including low
income, low education, racial and/or ethnic minority, and nicotine
dependence. For each of the “at-risk” groups, the demographic and
smoking-related variables were assessed and no signicant group
differences emerged. Therefore, analyses of treatment effects were
conducted without any covariates. Logistic regression was used to
assess abstinence rates at the 12-month follow-up (corresponding
to the end of treatment in the RM condition), and the 24-month
follow-up (corresponding to 12 month post treatment in the RM
condition). As can be seen in Table3, for those with relatively high
nicotine dependence (Fagerström Test for Nicotine Dependence > 5;
n= 1593), the RM condition showed higher abstinence rates than
the UC condition at two critical time points. At 12months, the absti-
nence rates were 42.2% versus 35.2% (OR=1.38, 95% CI=1.03%
to 1.85%, P=.031). At 24months, the abstinence rates were 45.0%
versus 38.8% (OR=1.31, 95% CI=1.01% to 1.73%, P=.046).
Lastly, in an effort to evaluate treatment integrity, participants in
both of the Forever Free treatment groups were asked whether they
received and read the intervention materials. With regard to receipt
of intervention, among responders at the 12-, 18-, and 24-month
follow-ups, 12.5% of the MM group and 8.0% of the RM group
did not endorse receipt of a single booklet. Those who reportedly did
Invited to Participate
n = 7589
Forever Free
Massed Mailing
n= 1127
Completed Follow-ups
6 month: n= 827 (73%)
12 month: n= 787 (70%)
18 month: n= 733 (65%)
24 month: n= 735 (65%)
Forever Free
Repeated Mailing
n= 1142
Completed Follow-ups
6 month: n= 814 (71%)
12 month: n= 802 (70%)
18 month: n = 715 (63%)
24 month: n= 735 (64%)
Usual Care
n = 1189
Completed Follow-ups
6 month: n= 906 (76%)
12 month: n= 874 (74%)
18 month: n= 798 (67%)
24 month: n= 798 (67%)
Agreed to Participate and Randomized
n= 5752 (76%)
Declined
n= 1881
Enrolled
n= 3458 (60%)
Excluded (failed to return baseline
or returned late)
n= 2294
Analysed
n= 1189
Analysed
n= 1127
Analysed
n = 1142
Figure1. CONSORT flow diagram.
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 00 5
not receive the intervention tended to have lower abstinence rates
by 6.6%–8.1% across follow-up points than those who reported
receiving the booklets, although the differences did not reach signi-
cance (Ps=.071–.161). With regard to whether participants read the
booklets, 90% of responders reported having read the intervention
booklets. At the 6- and 12-month follow-ups, abstinence rates were
42.8% and 43.70%, respectively, among those who reportedly read
the booklets, compared with 27% and 29% among those who did
not read the booklets (Ps < .03). The differences between those who
read and those who did not read the booklets dropped to approxi-
mately 5% at the 18- and 24-month follow-ups, and were no longer
signicant (Ps > .28). Finally, we compared smoking status for the
participants in the RM group who reported having read the booklets
to those in the UC group. Similar to the primary outcomes, absti-
nence rates were greater for the RM group, but the difference did not
reach signicance at any of the follow-ups (all Ps > .17).
Discussion
This randomized controlled trial tested the real-world effectiveness
of adding eight self-help relapse-prevention booklets to the stand-
ard services provided to smokers calling a state telephone quitline.
We found that the Forever Free booklets failed to produce signi-
cantly higher abstinence rates than usual care at any follow-up point
Table1. Demographic and Smoking Variables at Baseline by Intervention Condition
Usual care (n=1189) Massed mailing (n=1127) Repeated mailing (n=1142)
Demographic variables
Sex (%): male 51.7* 54.3 56.6*
Age: M (SD) 44.0 (13.5) 43.8 (13.9) 44.0 (13.4)
Race (%):white/Caucasian 79.4 78.4 79.4
Black/African American 10.6 10.2 10.1
Other 7.9 9.4 8.1
Refused to answer 2.0 2.2 2.3
Hispanic ethnicity (%) 7.1 8.9 9.7
Education (%):less than HS diploma 8.7 12.3 11.1
HS diploma or GED 35.9 35.4 35.3
College or technical school 54.2 50.3 52.7
Refused to answer 1.0 1.0 1.0
Insured (%) 74.6 76.3 74.5
Married/living together (%) 42.6 43.2 40.9
Household income (median category) $20–$30 000 $20–$30 000 $20–$30 000
Smoking-related variables
Cigarettes per day: M (SD) 19.2 (8.8)** 20.3 (9.3)** 19.8 (8.9)
FTND: M (SD) 5.1 (2.2) 5.2 (2.3) 5.2 (2.2)
Years smoked: M (SD) 22.3 (12.9) 22.9 (13.1) 22.5 (12.4)
Previous quit attempt: % 39.6 37.7 38.2
Live with smoker(s): % 36.9 38.7 37.5
Contemplation Ladder (0–11): M (SD) 9.9 (1.7) 9.8 (1.8) 9.8 (1.8)
SOC—action: % 54.2 53.1 54.6
FTND=Fagerström Test for Nicotine Dependence; GED=general equivalency diploma; HS=high school; SOC=Stages of Change.
*P < .05; **P < .01 between treatment groups.
Table2. Abstinence Rates (%) at Baseline and Follow-ups by Intervention Condition
Usual care (n=1189) Massed mailing (n=1127) Repeated mailing (n=1142) Full sample (N=3458)
Baseline 60.6 60.7 61.6 61.0
6months 41.3 40.2 44.1 41.9
12months 41.9 41.2 45.1 42.7
18months 43.9 43.0 45.1 44.0
24months 45.4 44.3 48.0 45.9
No statistically signicant group differences or interactions were found; results based on multiple imputation (20 data sets).
Table3. Abstinence Rates (%) at Baseline and Follow-ups by Intervention for Smokers With High Nicotine Dependence
Usual care (n=528) Massed mailing (n=536) Repeated mailing (n=529) All (n=1593)
Baseline 56.4 57.9 59.7 58.0
6months 36.4 38.5 42.0 39.0
12months 35.2* 37.3 42.2* 38.2
18months 37.0 40.4 43.1 40.2
24months 38.8* 41.3 45.0* 41.7
*P < .05 between intervention groups; results based on multiple imputation (20 data sets).
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 006
over 24months. However, post-hoc analyses revealed that among
individuals who reported high nicotine dependence at baseline, the
provision of the Forever Free booklets distributed over a 12-month
period produced higher quit rates relative to the standard quitline
services at 12 and 24months. Booklets delivered all at once did not
produce higher abstinence rates than usual care. This contrasts with
an earlier study of self-quitters, which found equivalent outcomes
for the two distribution schedules.22 It may be that the booklets pro-
vide little additional benet when they follow so closely in time a
multicomponent quitline intervention, whereas a longer distribution
schedule offers high-risk participants the benets of both reminders
of important concepts as well as maintained contact overtime.
The ndings from this study are in contrast to two earlier ran-
domized controlled trials that did observe a benet of providing
the Forever Free booklets to smokers.21–22 However, both these ear-
lier trials were based on unassisted recent quitters who proactively
sought assistance for relapse-prevention. By contrast, the partici-
pants in the current study were smokers seeking assistance to stop
smoking who were provided the Forever Free booklets as an adjunct
to the Quitline service, which already included the provision of free
NRT and counseling support. The conicting ndings between stud-
ies suggests the possibility that the Forever Free booklets, may be
useful to subgroups of smokers who might contact a Quitline, such
as those explicitly seeking assistance for RP, and perhaps heavily
addicted smokers. However, it appears that sending self-help relapse-
prevention materials to all Quitline callers adds little benet to deter-
ring relapse, and is therefore not recommended. This interpretation
is consistent with a previous nding in which the Forever Free book-
lets reduced relapse only among quitline callers who did not receive
pharmacotherapy.26 In the current study, all quitline callers received
NRT, and hence, it was not possible to test or replicate the previous
nding with non-NRTusers.
When added to existing interventions, minimal self-help inter-
ventions, particularly those delivered across an extended time-frame,
may have their greatest impact upon subgroups of smokers at greater
risk, such as those with high nicotine dependence or those receiving
substandard treatment (ie, self-quitters or quitline callers who do not
receive NRT). This conclusion is also consistent with a recent nding
that a similar self-help intervention for pregnant women was effec-
tive only for those in low-income households, perhaps due to lower
access to services, resources, and optimal treatments.27 It is impor-
tant to note, however, that the current intervention effect among
highly dependent smokers was a post-hoc nding for which chance
cannot be ruled out. Future effectiveness research is needed to repli-
cate the booklets’ impact among highly nicotine dependent smokers.
Another reason for lack of a treatment effect may be the high
abstinence rate (45.4%) achieved by the UC condition. To date, the
best telephone quitline outcomes in the literature have been found
with multiple counseling calls, with reported abstinence rates of
up to 27%,18,37,38 although one study found little benet beyond
two counseling calls.15 The high 24-month abstinence rate in the
UC condition may reect selection bias. That is, participants who
were available for the 2-week quitline call, agreed to participate in
the study, and returned their baseline questionnaire may have had
greater motivation to quit smoking. Another possibility is that,
although each assessment was relatively brief by design, the regu-
larly scheduled multiple assessments may have enhanced the percep-
tion of social support, which has been found to improve cessation
outcomes.39 The multiple assessments may have also produced a
“Hawthorne” or trial effect,40 resulting in higher than expected quit
rates. The multiple contacts combined with provision of NRT and
brief telephone counseling may have left little room for additional
improvement by a minimal self-help intervention.
In an effort to explore another potential reason for the lack of
outcome differences, we evaluated treatment integrity and found
that between 8%–12% of participants claimed to have not received
the Forever Free booklets. Although this nding did not impact the
overall treatment outcomes, it highlights the inherent challenges
that may be encountered in real-world effectiveness studies in which
the researchers do not have direct control of intervention delivery.
On the other hand, 90% of participants who reported receiving the
booklets said that they read them. The high treatment compliance is
consistent with high levels of satisfaction with the Forever Free inter-
vention reported by participants in the current study. However, simi-
lar to results regarding receipt of booklets, having read the booklets
did not impact the overall treatment outcomes.
This study has several strengths. It represents a real-world effec-
tiveness trial evaluating a self-help intervention delivered to quitline
clients via mail. The intervention draws on empirical and theoretical
research in RP. The study methodology allowed for evaluation of
24months of outcomes. Finally, the large, diverse sample provided
the statistical power to test both main effects, as well as moderating
variables.
The primary limitation of this study is related to generalizability.
There is considerable variability in the amount and type of services
provided by telephone quitlines in the United States and Canada.41
Services may include self-help materials, one or more proactive tel-
ephone counseling sessions, various types and amounts of cessa-
tion pharmacotherapy, or various combination of the above. The
NYSSQL offered at least two proactive telephone counseling ses-
sions, NRT, and educational materials consisting of a cessation guide
and information about nicotine withdrawal. The Forever Free book-
lets may be more effective among quitlines with fewer resources or
without pharmacotherapy, as suggested by prior research.26 Given
the low cost of the Forever Free booklets, testing this intervention
with telephone quitlines that have limited resources and provide
low-intensity services may still be warranted. An additional general-
izability-related factor is that the study sample consisted of predomi-
nantly Caucasian smokers who had some college or technical school
education. However, given that there were no outcome differences
by racial/ethnic minority status or by level of education, results from
this study are likely to generalize to populations consisting of vari-
able race, ethnicity, and education demographics.
Another limitation is the lack of biochemical verication of
cessation status due to logistical barriers. However, this decision
is consistent with research showing that there is little benet from
inclusion of biochemical verication in low-intensity interventions
without strong incentives to report false abstinence.42
In summary, the ndings from this study suggest that sending
self-help relapse-prevention booklets to all Quitline callers adds lit-
tle benet to deterring relapse, and is therefore not recommended.
However, selectively sending RP materials to callers explicitly seek-
ing assistance for RP, and those identied as highly dependent on
nicotine, may prove to be worthwhile.
Funding
This work was supported by National Cancer Institute of the National
Institutes of Health under award number R01CA137357. This work has also
been supported in part by the Biostatistics and Survey Methods Core Facilities
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 00 7
at the H. Lee Moftt Cancer Center and Research Institute, an NCI desig-
nated Comprehensive Cancer Center (P30CA76292). The content is solely the
responsibility of the authors and does not necessarily represent the ofcial
views of the National Institutes of Health.
Declaration of Interests
THB has received research support from Pzer, Inc. KMC has received grant
funding from the Pzer Corporation to study the impact of a hospital based
tobacco cessation intervention. He also receives funding as an expert witness
in litigation led against the tobacco industry. No other nancial disclosures or
conicts of interest were reported by the authors of this paper.
Acknowledgments
The authors would like to thank the study staff, Krissie Sismilich and Monica
Carrington, for their assistance with implementing this study.
References
1. Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and life-
time mortality risk in men: a prospective cohort study. Am J Epidemiol.
2012;175(10):1006–1012. doi:10.1093/aje/kwr466.
2. Papathanasiou A, Milionis H, Toumpoulis I, et al. Smoking cessation
is associated with reduced long-term mortality and the need for repeat
interventions after coronary artery bypass grafting. Eur J Cardiovasc Prev
Rehabil. 2007;13(3):448–550. doi:10.1097/HJR.0b013e3280403c68.
3. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, ces-
sation, and lung cancer in the UK since 1950: combination of national
statistics with two case-control studies. BMJ. 2000;321(7257):323–329.
doi:10.1136/bmj.321.7257.323.
4. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term
abstinence among untreated smokers. Addiction. 2004;99(1):29–38.
doi:10.1111/j.1360-0443.2004.00540.x.
5. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and
Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
U.S. Department of Health and Human Services, Public Health Service;
2008.
6. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of
abstinence: a meta-analysis. Addict Behav. 2008;33(12):1516–1520.
doi:10.1016/j.addbeh.2008.05.012.
7. Engstrom PF, Clapper ML, Schnoll RA. Approaches for Smoking
Cessation. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., eds.
Holland-Frei Cancer Medicine. 6th ed. Hamilton, ON: BC Decker; 2003.
8. Lichtenstein E, Zhu S, Tedeschi GJ. Smoking Cessation Quitlines: an
underrecognized intervention success story. Am Psychol. 2010;65(4):252–
261. doi:10.1037/a0018598.
9. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O’Connor R, Hyland
A. Reach, efcacy, and cost-effectiveness of free nicotine medication
give away programs. J Public Health Manag Pract. 2006;12(1):37–43.
doi:0.1097/00124784-200601000-00009.
10. Cummings KM, Hyland A, Carlin-Menter S, Mahoney M, Willett J, Juster
H. Costs of giving out free nicotine patches through a telephone quit
line. J Public Health Manag Pract. 2011;17(3):E16–E23. doi:10.1097/
PHH.0b013e3182113871.
11. Kahende JW, Loomis BR, Adhikari B, Marshall L. A review of economic
evaluations of tobacco control programs. Int J Environ Res Public Health.
2008;6(1):51–68. doi:doi.org/10.3390/ijerph6010051.
12. Krupski L, Cummings KM, Hyland A, et al. Cost and effectiveness of
combination nicotine replacement therapy in heavy smokers contacting a
quitline. J Smok Cessat. 2015; 1–10. doi:10.1017/jsc.2015.1.
13. Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: a cost-
effectiveness analysis. Int J Technol Assess Health Care. 2004;20(4):469–
474. doi:10.1017/S0266462304001370.
14. McAfee TA. Quitlines: a tool for research and dissemination of evi-
dence-based cessation practices. Am J Prev Med. 2007;33:S357–367.
doi:10.1016/j.amepre.2007.09.011.
15. Carlin-Menter S, Cummings KM, Celestino P, etal. Does offering more
support calls to smokers inuence quit success? J Public Health Manag
Pract. 2011;17(3):E9–15. doi:10.1097/PHH.0b013e318208e730.
16. Toll BA, Martino S, Latimer A, etal. Randomized trial: Quitline specialist
training in gain-framed vs standard-care messages for smoking cessation.
J Natl Cancer Inst. 2010;102(2):96–106. doi:10.1093/jnci/djp468.
17. Stead LF, Perera R, Lancaster T. Telephone counselling for smok-
ing cessation. Cochrane Database Syst Rev. 2006; 19(3): 1–87. doi:
10.1002/14651858.CD002850.pub2.
18. Zhu S-H, Anderson CM, Tedeschi GJ, et al. Evidence of real-world
effectiveness of a telephone quitline for smokers. N Engl J Med.
2002;347(14):1087–1093. doi:10.1056/NEJMsa020660.
19. Zhu S-H, Tedeschi G, Anderson CM, etal. Telephone counseling as adju-
vant treatment for nicotine replacement treatment in a “real-world” set-
ting. Prev Med. 2000;31(4):357–363. doi:10.1006/pmed.2000.0720.
20. Agboola S, Mcneill A, Coleman T, Bee JL. A systematic review
of the effectiveness of smoking relapse prevention interven-
tions for abstinent smokers. Addiction. 2010;105(8):1362–1380.
doi:10.1111/j.1360-0443.2010.02996.x.
21. Brandon TH, Collins BN, Juliano LM, Lazev AB. Preventing relapse
among former smokers: a comparison of minimal interventions via
telephone and mail. J Consult Clin Psychol. 2000;68(1):103–113.
doi:10.1037/0022-006X.68.1.103.
22. Brandon TH, Meade CD, Herzog TA, Chirikos TN, Webb MS, Cantor AB.
Efcacy and cost-effectiveness of a minimal intervention to prevent smok-
ing relapse: dismantling the effects of content versus contact. J Consult
Clin Psychol. 2004;72(5):797–808. doi:10.1037/0022-006X.72.5.797.
23. Chirikos TN, Herzog TA, Meade CD, Webb MS, Brandon TH. Cost-
effectiveness analysis of a complementary health intervention: the
case of smoking relapse prevention. Int J Technol Assess Health Care.
2004;20(4):475–480. doi:10.1017/S0266462304001382.
24. Marlatt GA. Relapse prevention: theoretical rationale and overview of the
model. In: Marlatt GH, Gordon JR, eds. Relapse Prevention. New York,
NY: Guilford; 1985.
25. Shiffman S, Shumaker SA, Abrams DB, etal. Models of smoking relapse.
Health Psychol. 1986;5(suppl):13–27. doi:10.1037/0278-6133.5.Suppl.13.
26. Sheffer CE, Stitzer M, Brandon TH, Bursac Z. Effectiveness of adding
relapse prevention materials to telephone counseling. J Subs Abuse Treat.
2010;39(1):71–77. doi:10.1016/j.jsat.2010.03.013.
27. Brandon TH, Simmons VN, Meade CD, etal. Self-help booklets for pre-
venting postpartum smoking relapse: a randomized trial. Am J Public
Health. 2012;102(11):2109–2115. doi:10.2105/AJPH.2012.300653.
28. Bandura A, ed. Social Learning Theory. New Jersey, NJ: Prentice-Hall;
1977.
29. Meade CD, Byrd JC. Patient literacy and the readability of smoking edu-
cation literature. Am J Public Health. 1989;79(2):204–205. doi:10.2105/
AJPH.79.2.204.
30. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The
Fagerström test for nicotine dependence: a revision of the Fagerström
tolerance questionnaire. Br J Addiction. 1991;86(9):1119–1127.
doi:10.1111/j.1360-0443.1991.tb01879.x.
31. Biener L, Abrams DB. Contemplation Ladder: validation of a measure
of readiness to consider smoking cessation. Health Psychol. 1991;10(5):
360–365. doi:10.1037/0278-6133.10.5.360.
32. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM,
Rossi JS. The process of smoking cessation: an analysis of precontempla-
tion, contemplation, and preparation stages of change. J Consult Clin
Psychol. 1991;59(2):295–304. doi:10.1037/0022-006X.59.2.295.
33. Simmons VN, Heckman BW, Ditre JW, Brandon TH. A measure of smoking
abstinence-related motivational engagement: development and initial vali-
dation. Nicotine Tob Res. 2010;12(4):432–427. doi:10.1093/ntr/ntq020.
34. Attkisson CC, Greeneld TK. Client satisfaction questionnaire-8 and ser-
vice satisfaction scale-30. In: Maruish ME, ed. The Use of Psychological
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
Nicotine & Tobacco Research, 2015, Vol. 00, No. 008
Testing for Treatment Planning and Outcome Assessment. New Jersey, NJ:
Lawrence Erlbaum Associates, Inc; 1994.
35. Schafer JL, ed. Analysis of Incomplete Multivariate Data. New York, NY:
Chapman & Hall; 1997.
36. Bernaards CA, Beline TR, Schafer JL. Robustness of a multivariate nor-
mal approximation for imputation of incomplete binary data. Stat Med.
2007;26(6):1368–1382. doi:10.1002/sim.2619.
37. Zhu S-H, Anderson CM, Tedeschi G, etal. The California Smokers’ Helpline:
Five Years of Experience. La Jolla, CA: University of California; 1998.
38. Zhu S-H, Tedeschi GJ, Anderson CM, Pierce JP. Telephone counseling
for smoking cessation: what’s in a call? J Counsel Develop. 1996;75(2):
93–102. doi:10.1002/j.1556–6676.1996.tb02319.x.
39. Mermelstein R, Cohen S, Lichtenstein E, Baer JS, Kamarck T. Social sup-
port and smoking cessation and maintenance. J Consult Clin Psychol.
1986;54(4):447–453. doi:10.1037/0022-006X.54.4.447.
40. McCarney R, Warner J, Iliffe S, van Haselen R, Grifn M, Fisher P. The
Hawthorne Effect: a randomised, controlled trial. BMC Med Research
Methodol. 2007;7(1):30. doi:10.1186/1471-2288-7-30.
41. Cummins SE, Bailey L, Campbell S, Koon-Kirby C, Zhu SH. Tobacco
cessation quitlines in North America: a descriptive study. Tob Control.
2007;16(suppl 1):i9–i15. doi:10.1136/tc.2007.020370.
42. Benowitz NL, Jacob P III, Ahijevych K. Biochemical verication of
tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149–159.
doi:10.1080/14622200210123581.
at Society for Research on Nicotine and Tobacco member access on April 29, 2015http://ntr.oxfordjournals.org/Downloaded from
... The distribution of the cohort across sex and age categories at the start of the model was designed to reflect the distribution of smokers in the United Kingdom. The proportion of male and female adults and mortality risk in each of the 3 age categories (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), and 651 years old) was determined from general population data. 32,33 Smoking prevalence data 34 were applied to these data to calculate the distribution across age and sex groups for a representative sample of 10,000 UK smokers (Appendix Table 2 in the Supplementary Material found at https://doi.org/ ...
... The proportion of male and female adults and mortality risk in each of the 3 age categories (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), and 651 years old) was determined from general population data. 32,33 Smoking prevalence data 34 were applied to these data to calculate the distribution across age and sex groups for a representative sample of 10,000 UK smokers (Appendix Table 2 in the Supplementary Material found at https://doi.org/ 10.1016/j.jval.2020.12.012). ...
Article
Full-text available
Background Cigarette smoking is one of the leading causes of early death. Varenicline [Champix (UK), Pfizer Europe MA EEIG, Brussels, Belgium; or Chantix (USA), Pfizer Inc., Mission, KS, USA], bupropion (Zyban; GlaxoSmithKline, Brentford, UK) and nicotine replacement therapy are licensed aids for quitting smoking in the UK. Although not licensed, e-cigarettes may also be used in English smoking cessation services. Concerns have been raised about the safety of these medicines and e-cigarettes. Objectives To determine the clinical effectiveness, safety and cost-effectiveness of smoking cessation medicines and e-cigarettes. Design Systematic reviews, network meta-analyses and cost-effectiveness analysis informed by the network meta-analysis results. Setting Primary care practices, hospitals, clinics, universities, workplaces, nursing or residential homes. Participants Smokers aged ≥ 18 years of all ethnicities using UK-licensed smoking cessation therapies and/or e-cigarettes. Interventions Varenicline, bupropion and nicotine replacement therapy as monotherapies and in combination treatments at standard, low or high dose, combination nicotine replacement therapy and e-cigarette monotherapies. Main outcome measures Effectiveness – continuous or sustained abstinence. Safety – serious adverse events, major adverse cardiovascular events and major adverse neuropsychiatric events. Data sources Ten databases, reference lists of relevant research articles and previous reviews. Searches were performed from inception until 16 March 2017 and updated on 19 February 2019. Review methods Three reviewers screened the search results. Data were extracted and risk of bias was assessed by one reviewer and checked by the other reviewers. Network meta-analyses were conducted for effectiveness and safety outcomes. Cost-effectiveness was evaluated using an amended version of the Benefits of Smoking Cessation on Outcomes model. Results Most monotherapies and combination treatments were more effective than placebo at achieving sustained abstinence. Varenicline standard plus nicotine replacement therapy standard (odds ratio 5.75, 95% credible interval 2.27 to 14.90) was ranked first for sustained abstinence, followed by e-cigarette low (odds ratio 3.22, 95% credible interval 0.97 to 12.60), although these estimates have high uncertainty. We found effect modification for counselling and dependence, with a higher proportion of smokers who received counselling achieving sustained abstinence than those who did not receive counselling, and higher odds of sustained abstinence among participants with higher average dependence scores. We found that bupropion standard increased odds of serious adverse events compared with placebo (odds ratio 1.27, 95% credible interval 1.04 to 1.58). There were no differences between interventions in terms of major adverse cardiovascular events. There was evidence of increased odds of major adverse neuropsychiatric events for smokers randomised to varenicline standard compared with those randomised to bupropion standard (odds ratio 1.43, 95% credible interval 1.02 to 2.09). There was a high level of uncertainty about the most cost-effective intervention, although all were cost-effective compared with nicotine replacement therapy low at the £20,000 per quality-adjusted life-year threshold. E-cigarette low appeared to be most cost-effective in the base case, followed by varenicline standard plus nicotine replacement therapy standard. When the impact of major adverse neuropsychiatric events was excluded, varenicline standard plus nicotine replacement therapy standard was most cost-effective, followed by varenicline low plus nicotine replacement therapy standard. When limited to licensed interventions in the UK, nicotine replacement therapy standard was most cost-effective, followed by varenicline standard. Limitations Comparisons between active interventions were informed almost exclusively by indirect evidence. Findings were imprecise because of the small numbers of adverse events identified. Conclusions Combined therapies of medicines are among the most clinically effective, safe and cost-effective treatment options for smokers. Although the combined therapy of nicotine replacement therapy and varenicline at standard doses was the most effective treatment, this is currently unlicensed for use in the UK. Future work Researchers should examine the use of these treatments alongside counselling and continue investigating the long-term effectiveness and safety of e-cigarettes for smoking cessation compared with active interventions such as nicotine replacement therapy. Study registration This study is registered as PROSPERO CRD42016041302. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 59. See the NIHR Journals Library website for further project information.
... The distribution of the cohort across sex and age categories at the start of the model was designed to reflect the distribution of smokers in the United Kingdom. The proportion of male and female adults and mortality risk in each of the 3 age categories (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), and 651 years old) was determined from general population data. 32,33 Smoking prevalence data 34 were applied to these data to calculate the distribution across age and sex groups for a representative sample of 10,000 UK smokers (Appendix Table 2 in the Supplementary Material found at https://doi.org/ ...
... The proportion of male and female adults and mortality risk in each of the 3 age categories (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), and 651 years old) was determined from general population data. 32,33 Smoking prevalence data 34 were applied to these data to calculate the distribution across age and sex groups for a representative sample of 10,000 UK smokers (Appendix Table 2 in the Supplementary Material found at https://doi.org/ 10.1016/j.jval.2020.12.012). ...
Article
Full-text available
Objectives Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other. Previous cost-effectiveness analyses have not fully accounted for adverse effects nor compared all cessation aids. The objective was to determine the relative cost-effectiveness of cessation aids in the United Kingdom. Methods An established Markov cohort model was adapted to incorporate health outcomes and costs due to depression and self-harm associated with cessation aids, alongside other health events. Relative efficacy in terms of abstinence and major adverse neuropsychiatric events was informed by a systematic review and network meta-analysis. Base case results are reported for UK-licensed interventions only. Two sensitivity analyses are reported, one including unlicensed interventions and another comparing all cessation aids but removing the impact of depression and self-harm. The sensitivity of conclusions to model inputs was assessed by calculating the expected value of partial perfect information. Results When limited to UK-licensed interventions, varenicline standard-dose and NRT standard-dose were most cost-effective. Including unlicensed interventions, e-cigarette low-dose appeared most cost-effective followed by varenicline standard-dose + bupropion standard-dose combined. When the impact of depression and self-harm was excluded, varenicline standard-dose + NRT standard-dose was most cost-effective, followed by varenicline low-dose + NRT standard-dose. Conclusion Although found to be most cost-effective, combined therapy is currently unlicensed in the United Kingdom and the safety of e-cigarettes remains uncertain. The value-of-information analysis suggested researchers should continue to investigate the long-term effectiveness and safety outcomes of e-cigarettes in studies with active comparators.
... Later studies that added the intervention to existing Quitline or in-person cessation counseling did not appear to increase efficacy. 37,38 When superimposed on an effective cessation intervention, self-help interventions may have minimal additional benefit. ...
Article
Full-text available
Background Abstaining from smoking after a cancer diagnosis is critical to mitigating the risk of multiple adverse health outcomes. Although many patients with cancer attempt to quit smoking, the majority relapse. The current randomized controlled trial evaluated the efficacy of adapting an evidence‐based smoking relapse prevention (SRP) intervention for patients with cancer. Methods The trial enrolled 412 patients newly diagnosed with cancer who had recently quit smoking. Participants were randomized to usual care (UC) or SRP. Participants in the UC group received the institution's standard of care for treating tobacco use. Participants in the SRP group in addition received a targeted educational DVD plus a validated self‐help intervention for preventing smoking relapse. The primary outcome was smoking abstinence at 2 months, 6 months, and 12 months. Results Abstinence rates for participants in the SRP and UC groups were 75% versus 71% at 2 months and 69% versus 64% at 6 months (Ps > .20). At 12 months, abstinence rates among survivors were 68% for those in the SRP group and 63% for those in the UC group (P = .38). Post hoc analyses revealed that across 2 months and 6 months, patients who were married/partnered were more likely to be abstinent after SRP than UC (P = .03). Conclusions A smoking relapse prevention intervention did not reduce relapse rates overall, but did appear to have benefited those participants who had the social support of a partner. Future work is needed to extend this effect to the larger population of patients.
... PNs could, for instance, explore possibilities to refer patients to complementary smoking relapse interventions [46] in addition to PN-led counseling. PNs could actively refer patients to additional evidence-based, behavioral support focusing on training coping skills [24,47,48] or could recommend additional pharmacotherapeutic support [49,50], known to be effective to prevent smoking relapse. By supporting smokers to additionally use such effective relapse prevention strategies it could be possible to achieve improved abstinence rates that are sustained over a longer time period. ...
Preprint
Objective To conduct an economic evaluation of a tailored e-learning program, which successfully improved practice nurses’ smoking cessation guideline adherence. Methods The economic evaluation was embedded in a randomized controlled trial, in which 269 practice nurses recruited 388 smoking patients. Cost-effectiveness was assessed using guideline adherence as effect measure on practice nurse level, and continued smoking abstinence on patient level. Cost-utility was assessed on patient level, using patients’ Quality Adjusted Life Years (QALYs) as effect measure. Results The e-learning program was likely to be cost-effective on practice nurse level, as adherence to an additional guideline step cost €1,586. On patient level, cost-effectiveness was slightly likely after six months (cost per additional quitter: €7,126), but not after twelve months. The cost-utility analysis revealed slight cost-effectiveness (cost per QALY gained: €18,431) on patient level. Conclusion Providing practice nurses with a tailored e-learning program is cost-effective to improve their smoking cessation counseling.Though, cost-effectiveness on patient level was not found after twelve months, potentially resulting from smoking relapse. Practice implications Widespread implementation of the e-learning program can improve the quality of smoking cessation care in general practice. Strategies to prevent patients’ smoking relapse should be further explored to improve patients’ long-term abstinence.
... Willpower to "tough it out" (Sobell et al., 1995, p. 216) 49 Thought about negative consequences (Sobell et al., 1995) 46 Self-help booklets (Brandon et al., 2016;Unrod et al., 2015) n.a. ...
Article
Full-text available
Millions of people change risky, health-related behaviors and maintain those changes. However, they often take years to change, and their unhealthy behaviors may harm themselves and others and constitute a significant cost to society. A review—similar in nature to a scoping review—was done of the literature related to long-term health behavior change in six areas: alcohol, cocaine and heroin misuse, gambling, smoking, and overeating. Based on the limited research available, reasons for change and strategies for changing and for maintaining change were also reviewed. Fifty years of research clearly indicate that as people age, in the case of alcohol, heroin and cocaine misuse, smoking, and gambling, 80–90 percent moderate or stop their unhealthy behaviors. The one exception is overeating; only 20 percent maintain their weight loss. Most of these changes, when they occur, appear to be the result of self-guided change. More ways to accelerate self-guided, health-related behavior change need to be developed and disseminated.
Article
Background: People from lower socioeconomic groups are more likely to smoke and less likely to succeed in achieving abstinence, making tobacco smoking a leading driver of health inequalities. Contextual factors affecting subpopulations may moderate the efficacy of individual-level smoking cessation interventions. It is not known whether any intervention performs differently across socioeconomically-diverse populations and contexts. Objectives: To assess whether the effects of individual-level smoking cessation interventions on combustible tobacco cigarette use differ by socioeconomic groups, and their potential impact on health equalities. Search methods: We searched the Cochrane Database of Systematic Reviews from inception to 1 May 2023 for Cochrane reviews investigating individual-level smoking cessation interventions. We selected studies included in these reviews that met our criteria. We contacted study authors to identify further eligible studies. Selection criteria: We included parallel, cluster or factorial randomised controlled trials (RCTs) investigating any individual-level smoking cessation intervention which encouraged complete cessation of combustible tobacco cigarette use compared to no intervention, placebo, or another intervention in adults. Studies must have assessed or reported smoking quit rates, split by any measure of socioeconomic status (SES) at longest follow-up (≥ six months), and been published in 2000 or later. Data collection and analysis: We followed standard Cochrane methods for screening, data extraction, and risk of bias assessment. We assessed the availability of smoking abstinence data by SES in lieu of selective reporting. The primary outcome was smoking cessation quit rates, split by lower and higher SES, at the longest follow-up (≥ six months). Where possible, we calculated ratios of odds ratios (ROR) with 95% confidence intervals (CIs) for each study, comparing lower to higher SES. We pooled RORs by intervention type in random-effects meta-analyses, using the generic inverse-variance method. We subgrouped by type of SES indicator and economic classification of the study country. We summarised all evidence in effect direction plots and categorised the intervention impact on health equality as: positive (evidence that the relative effect of the intervention on quit rates was greater in lower rather than higher SES groups), possibly positive, neutral, possibly neutral, possibly negative, negative, no reported statistically significant difference, or unclear. We evaluated certainty using GRADE. Main results: We included 77 studies (73 from high-income countries), representing 127,791 participants. We deemed 12 studies at low overall risk of bias, 13 at unclear risk, and the remaining 52 at high risk. Included studies investigated a range of pharmacological interventions, behavioural support, or combinations of these. Pharmacological interventions We found very low-certainty evidence for all the main pharmacological interventions compared to control. Evidence on cytisine (ROR 1.13, 95% CI 0.73 to 1.74; 1 study, 2472 participants) and nicotine electronic cigarettes (ROR 4.57, 95% CI 0.88 to 23.72; 1 study, 989 participants) compared to control indicated a greater relative effect of these interventions on quit rates in lower compared to higher SES groups, suggesting a possibly positive impact on health equality. CIs for both estimates included the possibility of no clinically important difference and of favouring higher SES groups. There was a lower relative effect of bupropion versus placebo on quit rates in lower compared to higher SES groups, indicating a possibly negative impact on health equality (ROR 0.05, 95% CI 0.00 to 1.00; from 1 of 2 studies, 354 participants; 1 study reported no difference); however, the CI included the possibility of no clinically important difference. We could not determine the intervention impact of combination or single-form nicotine replacement therapy on relative quit rates by SES. No studies on varenicline versus control were included. Behavioural interventions We found low-certainty evidence of lower quit rates in lower compared to higher SES groups for print-based self-help (ROR 0.85, 95% CI 0.52 to 1.38; 3 studies, 4440 participants) and text-messaging (ROR 0.76, 95% CI 0.47 to 1.23; from 3 of 4 studies, 5339 participants; 1 study reported no difference) versus control, indicating a possibly negative impact on health equality. CIs for both estimates included the possibility of no clinically important difference and of favouring lower SES groups. There was very low-certainty evidence of quit rates favouring higher SES groups for financial incentives compared to balanced intervention components. However, the CI included the possibility of no clinically important difference and of favouring lower SES groups (ROR 0.91, 95% CI 0.45 to 1.85; from 5 of 6 studies, 3018 participants; 1 study reported no difference). This indicates a possibly negative impact on health equality. There was very low-certainty evidence of no difference in quit rates by SES for face-to-face counselling compared to less intensive counselling, balanced components, or usual care. However, the CI included the possibility of favouring lower and higher SES groups (ROR 1.26, 95% CI 0.18 to 8.93; from 1 of 6 studies, 294 participants; 5 studies reported no difference), indicating a possibly neutral impact. We found very low-certainty evidence of a greater relative effect of telephone counselling (ROR 4.31, 95% CI 1.28 to 14.51; from 1 of 7 studies, 903 participants; 5 studies reported no difference, 1 unclear) and internet interventions (ROR 1.49, 95% CI 0.99 to 2.25; from 1 of 5 studies, 4613 participants; 4 studies reported no difference) versus control on quit rates in lower versus higher SES groups, suggesting a possibly positive impact on health equality. The CI for the internet intervention estimate included the possibility of no difference. Although the CI for the telephone counselling estimate only favoured lower SES groups, most studies narratively reported no clear evidence of interaction effects. Authors' conclusions: Currently, there is no clear evidence to support the use of differential individual-level smoking cessation interventions for people from lower or higher SES groups, or that any one intervention would have an effect on health inequalities. This conclusion may change as further data become available. Many studies did not report sufficient data to be included in a meta-analysis, despite having tested the association of interest. Further RCTs should collect, analyse, and report quit rates by measures of SES, to inform intervention development and ensure recommended interventions do not exacerbate but help reduce health inequalities caused by smoking.
Article
Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters relapse over time. Several interventions have been proposed to help prevent relapse. Objectives: To assess whether specific interventions for relapse prevention reduce the proportion of recent quitters who return to smoking. Search methods: We searched the Cochrane Tobacco Addiction Group trials register, clinicaltrials.gov, and the ICTRP in May 2019 for studies mentioning relapse prevention or maintenance in their title, abstracts, or keywords. Selection criteria: Randomised or quasi-randomised controlled trials of relapse prevention interventions with a minimum follow-up of six months. We included smokers who quit on their own, were undergoing enforced abstinence, or were participating in treatment programmes. We included studies that compared relapse prevention interventions with a no intervention control, or that compared a cessation programme with additional relapse prevention components with a cessation programme alone. Data collection and analysis: We used standard methodological procedures expected by Cochrane. Main results: We included 81 studies (69,094 participants), five of which are new to this update. We judged 22 studies to be at high risk of bias, 53 to be at unclear risk of bias, and six studies to be at low risk of bias. Fifty studies included abstainers, and 30 studies helped people to quit and then tested treatments to prevent relapse. Twenty-eight studies focused on special populations who were abstinent because of pregnancy (19 studies), hospital admission (six studies), or military service (three studies). Most studies used behavioural interventions that tried to teach people skills to cope with the urge to smoke, or followed up with additional support. Some studies tested extended pharmacotherapy. We focused on results from those studies that randomised abstainers, as these are the best test of relapse prevention interventions. Of the 12 analyses we conducted in abstainers, three pharmacotherapy analyses showed benefits of the intervention: extended varenicline in assisted abstainers (2 studies, n = 1297, risk ratio (RR) 1.23, 95% confidence interval (CI) 1.08 to 1.41, I2 = 82%; moderate-certainty evidence), rimonabant in assisted abstainers (1 study, RR 1.29, 95% CI 1.08 to 1.55), and nicotine replacement therapy (NRT) in unaided abstainers (2 studies, n = 2261, RR 1.24, 95% Cl 1.04 to 1.47, I2 = 56%). The remainder of analyses of pharmacotherapies in abstainers had wide confidence intervals consistent with both no effect and a statistically significant effect in favour of the intervention. These included NRT in hospital inpatients (2 studies, n = 1078, RR 1.23, 95% CI 0.94 to 1.60, I2 = 0%), NRT in assisted abstainers (2 studies, n = 553, RR 1.04, 95% CI 0.77 to 1.40, I2 = 0%; low-certainty evidence), extended bupropion in assisted abstainers (6 studies, n = 1697, RR 1.15, 95% CI 0.98 to 1.35, I2 = 0%; moderate-certainty evidence), and bupropion plus NRT (2 studies, n = 243, RR 1.18, 95% CI 0.75 to 1.87, I2 = 66%; low-certainty evidence). Analyses of behavioural interventions in abstainers did not detect an effect. These included studies in abstinent pregnant and postpartum women at the end of pregnancy (8 studies, n = 1523, RR 1.05, 95% CI 0.99 to 1.11, I2 = 0%) and at postpartum follow-up (15 studies, n = 4606, RR 1.02, 95% CI 0.94 to 1.09, I2 = 3%), studies in hospital inpatients (5 studies, n = 1385, RR 1.10, 95% CI 0.82 to 1.47, I2 = 58%), and studies in assisted abstainers (11 studies, n = 5523, RR 0.98, 95% CI 0.87 to 1.11, I2 = 52%; moderate-certainty evidence) and unaided abstainers (5 studies, n = 3561, RR 1.06, 95% CI 0.96 to 1.16, I2 = 1%) from the general population. Authors' conclusions: Behavioural interventions that teach people to recognise situations that are high risk for relapse along with strategies to cope with them provided no worthwhile benefit in preventing relapse in assisted abstainers, although unexplained statistical heterogeneity means we are only moderately certain of this. In people who have successfully quit smoking using pharmacotherapy, there were mixed results regarding extending pharmacotherapy for longer than is standard. Extended treatment with varenicline helped to prevent relapse; evidence for the effect estimate was of moderate certainty, limited by unexplained statistical heterogeneity. Moderate-certainty evidence, limited by imprecision, did not detect a benefit from extended treatment with bupropion, though confidence intervals mean we could not rule out a clinically important benefit at this stage. Low-certainty evidence, limited by imprecision, did not show a benefit of extended treatment with nicotine replacement therapy in preventing relapse in assisted abstainers. More research is needed in this area, especially as the evidence for extended nicotine replacement therapy in unassisted abstainers did suggest a benefit.
Article
Objective: To conduct an economic evaluation of a tailored e-learning program, which successfully improved practice nurses' smoking cessation guideline adherence. Methods: The economic evaluation was embedded in a randomized controlled trial, in which 269 practice nurses recruited 388 smoking patients. Cost-effectiveness was assessed using guideline adherence as effect measure on practice nurse level, and continued smoking abstinence on patient level. Cost-utility was assessed on patient level, using patients' Quality Adjusted Life Years (QALYs) as effect measure. Results: The e-learning program was likely to be cost-effective on practice nurse level, as adherence to an additional guideline step cost €1,586. On patient level, cost-effectiveness was slightly likely after six months (cost per additional quitter: €7,126), but not after twelve months. The cost-utility analysis revealed slight cost-effectiveness (cost per QALY gained: €18,431) on patient level. Conclusion: Providing practice nurses with a tailored e-learning program is cost-effective to improve their smoking cessation counseling. Though, cost-effectiveness on patient level was not found after twelve months, potentially resulting from smoking relapse. Practice implications: Widespread implementation of the e-learning program can improve the quality of smoking cessation care in general practice. Strategies to prevent patients' smoking relapse should be further explored to improve patients' long-term abstinence.
Article
Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters relapse over time. Several interventions have been proposed to help prevent relapse. Objectives: To assess whether specific interventions for relapse prevention reduce the proportion of recent quitters who return to smoking. Search methods: We searched the Cochrane Tobacco Addiction Group trials register, clinicaltrials.gov, and the ICTRP in February 2018 for studies mentioning relapse prevention or maintenance in their title, abstracts, or keywords. Selection criteria: Randomised or quasi-randomised controlled trials of relapse prevention interventions with a minimum follow-up of six months. We included smokers who quit on their own, were undergoing enforced abstinence, or were participating in treatment programmes. We included studies that compared relapse prevention interventions with a no intervention control, or that compared a cessation programme with additional relapse prevention components with a cessation programme alone. Data collection and analysis: We used standard methodological procedures expected by Cochrane. Main results: We included 77 studies (67,285 participants), 15 of which are new to this update. We judged 21 studies to be at high risk of bias, 51 to be at unclear risk of bias, and five studies to be at low risk of bias. Forty-eight studies included abstainers, and 29 studies helped people to quit and then tested treatments to prevent relapse. Twenty-six studies focused on special populations who were abstinent because of pregnancy (18 studies), hospital admission (five studies), or military service (three studies). Most studies used behavioural interventions that tried to teach people skills to cope with the urge to smoke, or followed up with additional support. Some studies tested extended pharmacotherapy.We focused on results from those studies that randomised abstainers, as these are the best test of relapse prevention interventions. Of the 12 analyses we conducted in abstainers, three pharmacotherapy analyses showed benefits of the intervention: extended varenicline in assisted abstainers (2 studies, n = 1297, risk ratio (RR) 1.23, 95% confidence interval (CI) 1.08 to 1.41, I² = 82%; moderate certainty evidence), rimonabant in assisted abstainers (1 study, RR 1.29, 95% CI 1.08 to 1.55), and nicotine replacement therapy (NRT) in unaided abstainers (2 studies, n = 2261, RR 1.24, 95% Cl 1.04 to 1.47, I² = 56%). The remainder of analyses of pharmacotherapies in abstainers had wide confidence intervals consistent with both no effect and a statistically significant effect in favour of the intervention. These included NRT in hospital inpatients (2 studies, n = 1078, RR 1.23, 95% CI 0.94 to 1.60, I² = 0%), NRT in assisted abstainers (2 studies, n = 553, RR 1.04, 95% CI 0.77 to 1.40, I² = 0%; low certainty evidence), extended bupropion in assisted abstainers (6 studies, n = 1697, RR 1.15, 95% CI 0.98 to 1.35, I² = 0%; moderate certainty evidence), and bupropion plus NRT (2 studies, n = 243, RR 1.18, 95% CI 0.75 to 1.87, I² = 66%; low certainty evidence). Analyses of behavioural interventions in abstainers did not detect an effect. These included studies in abstinent pregnant and postpartum women at end of pregnancy (8 studies, n = 1523, RR 1.05, 95% CI 0.99 to 1.11, I² = 0%) and at postpartum follow-up (15 studies, n = 4606, RR 1.02, 95% CI 0.94 to 1.09, I² = 3%), studies in hospital inpatients (4 studies, n = 1300, RR 0.95, 95% CI 0.81 to 1.11, I² = 0%), and studies in assisted abstainers (10 studies, n = 5408, RR 0.99, 95% CI 0.87 to 1.13, I² = 56%; moderate certainty evidence) and unaided abstainers (5 studies, n = 3561, RR 1.06, 95% CI 0.96 to 1.16, I² = 1%) from the general population. Authors' conclusions: Behavioural interventions that teach people to recognise situations that are high risk for relapse along with strategies to cope with them provided no worthwhile benefit in preventing relapse in assisted abstainers, although unexplained statistical heterogeneity means we are only moderately certain of this. In people who have successfully quit smoking using pharmacotherapy, there were mixed results regarding extending pharmacotherapy for longer than is standard. Extended treatment with varenicline helped to prevent relapse; evidence for the effect estimate was of moderate certainty, limited by unexplained statistical heterogeneity. Moderate-certainty evidence, limited by imprecision, did not detect a benefit from extended treatment with bupropion, though confidence intervals mean we could not rule out a clinically important benefit at this stage. Low-certainty evidence, limited by imprecision, did not show a benefit of extended treatment with nicotine replacement therapy in preventing relapse in assisted abstainers. More research is needed in this area, especially as the evidence for extended nicotine replacement therapy in unassisted abstainers did suggest a benefit.
Article
Background: Identifying effective relapse prevention interventions is a vital step to help smokers maintain abstinence for the long term. Aims: The purpose of this study is to determine if providing recently quit smokers with self-directed relapse prevention booklets is effective at maintaining abstinence after intensive group smoking cessation treatment. Method: Two hundred and twenty-five participants were randomized to receive Forever Free (FF) relapse prevention booklets or a control booklet (Surgeon General's report, SG) at the end of a 6-week group treatment program. Participants were then contacted by phone to assess whether they had read the materials. Smoking status was assessed 6 months after their target quit date. Primary analyses focused on the 115 participants who quit at the end of treatment. Results: There was no difference in the 6-month quit rate between groups (40.7% quit FF vs. 44.6% quit SG, p = .67). The FF group read a significantly smaller proportion of the materials versus the control booklet (20.0% read most or all of FF vs. 72.0% of SG, p < .001). Conclusion: Forever Free self-directed relapse prevention booklets did not reduce relapse or enhance cessation over general tobacco and health information when added to intensive group smoking cessation treatment. However, this study lacked power to detect a small but clinically meaningful positive effect.
Article
Full-text available
Examined the role of social support in smoking cessation and maintenance in 2 longitudinal, prospective studies with 64 Ss each (mean ages 38.4 yrs and 38.8 yrs). Three kinds of support factors were assessed: support from a partner directly related to quitting, perceptions of the availability of general (i.e., nonsmoking) support resources, and the presence of smokers in Ss' social networks. Ss were smokers in cessation programs. Corroborated smoking status was obtained through 12 mo posttreatment. There was evidence for all 3 support factors, but they operated at different points in the process of cessation and maintenance. High levels of partner support and of the perceived availability of general support were associated with cessation and with short-term (to 3 mo posttreatment) maintenance of abstinence. The presence of smokers in Ss' social networks was a hindrance to maintenance and significantly differentiated between relapsers and long-term (12-mo) abstainers. (33 ref) (PsycINFO Database Record (c) 2012 APA, all rights reserved)
Article
An error has been noted in the above mentioned article by Krupski et al. In the discussion section in the fourth paragraph, 'greater than 15 cigarettes per day' should read 'greater than or equal to 10 cigarettes per day'. The corrected sentence should read: This finding mirrors the results of a recent randomised trial that found less of an effect of combination NRT for heavier smokers, defined as smoking greater than or equal to 10 cigarettes per day (Smith et al., 2013).
Article
Telephone counseling for smoking cessation has been gaining popularity as studies have demonstrated its efficacy. What comprises a successful program, however, has not yet been detailed in the literature. In this article, an innovative telephone counseling intervention for smoking cessation is described, with attention to the clinical issues of client assessment, motivation, self‐efficacy, planning, coping, relapse‐sensitive call scheduling, and self‐image. Counselor training and supervision issues, ethical and legal considerations regarding this form of service delivery, and suggestions for future direction also are outlined.
Book
Introduction Assumptions EM and Inference by Data Augmentation Methods for Normal Data More on the Normal Model Methods for Categorical Data Loglinear Models Methods for Mixed Data Further Topics Appendices References Index